Molecular profiling for early patient identification — 2 of 2

Testing for FGFR2 fusions or rearrangements can inform treatment decisions in CCA

The high frequency of actionable alterations in patients with CCA strongly supports the use of molecular testing in this population17

FGFR2 fusions have a wide range of fusion partners.17 Therefore, to identify patients with FGFR2 fusions, it is important to select an appropriate assay that:

White tick

Can detect FGFR2 fusions (which are distinct from FGFR2 point mutations)17,24,25

White tick

Can detect all FGFR2 fusions, including those with known or unknown fusion partners17,24,25

ESMO recommends routine use of multigene NGS to detect level 1 genomic alterations (IDH1 mutations, FGFR2 fusions, NTRK fusions and MSI-H) in advanced CCA26